Infectious Disease Unit, Samson Assuta Ashdod University Hospital, Israel; Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheba, Israel.
Microbiology Laboratory, Samson Assuta Ashdod University Hospital, Israel; Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheba, Israel.
Vaccine. 2021 Sep 24;39(40):5729-5731. doi: 10.1016/j.vaccine.2021.08.088. Epub 2021 Aug 30.
Concerns were raised over an increase in Bell's palsy, herpes simplex and herpes zoster after BNT162b2 vaccination, all are manifestations of herpesviruses reactivation. As herpesviruses commonly reactivate in the oropharynx, we have hypothesized that oropharyngeal shedding of herpesviruses will increase after vaccination.
Immune-competent Adults, excluding those using topical steroids or manifesting symptomatic herpesvirus infection, were sampled before BNT162b2 vaccination and one week after. Herpesviruses 1-7 shedding was tested with a multiplexed PCR.
In 103 paired samples the prevalence of herpesviruses was similar before and after vaccination: HSV1, 3.9% vs. 5.8% (p = 0.75); HSV2, 0% vs. 1% (p = not applicable, NA); VZV, 0% vs. 0% (p = NA); EBV, 14.6% vs. 17.5% (p = 0.63); CMV, 0% vs. 0% (p = NA); HHV6, 4.9% vs. 7.8% (p = 0.55); HHV7, 71.8% vs. 72.8% (p = 1); any herpesvirus, 73.8% vs. 74.8% (p = 1).
We did not find evidence for increased oropharyngeal reactivation of herpesviruses one week after BNT162b2.
接种 BNT162b2 后，人们对贝尔氏麻痹、单纯疱疹和带状疱疹的发病率增加提出了担忧，这些都是疱疹病毒再激活的表现。由于疱疹病毒通常在口咽部重新激活，我们假设接种疫苗后口咽部疱疹病毒的脱落会增加。
免疫功能正常的成年人（不包括使用局部类固醇或表现出有症状的疱疹病毒感染的人）在接种 BNT162b2 之前和一周后接受了采样。使用多重 PCR 检测了 1-7 型疱疹病毒的脱落情况。
在 103 对配对样本中，接种前后疱疹病毒的流行率相似：HSV1，3.9% vs. 5.8%（p=0.75）；HSV2，0% vs. 1%（p=不适用，NA）；VZV，0% vs. 0%（p=NA）；EBV，14.6% vs. 17.5%（p=0.63）；CMV，0% vs. 0%（p=NA）；HHV6，4.9% vs. 7.8%（p=0.55）；HHV7，71.8% vs. 72.8%（p=1）；任何疱疹病毒，73.8% vs. 74.8%（p=1）。
我们没有发现接种 BNT162b2 后一周口咽部疱疹病毒再激活增加的证据。
